Cordis Endovascular, A Division Of Cordis Corporation, Supports Peripheral Artery Disease Guidelines Released By The American Heart Association And American College of Cardiology
WARREN, N.J., Dec. 6 /PRNewswire/ -- Cordis Endovascular, a division of Cordis Corporation, supports the treatment guidelines for peripheral artery disease (PAD) released today by the American Heart Association (AHA) and American College of Cardiology (ACC). These guidelines were developed to help accurately diagnose and treat the more than 12 million Americans with PAD, a debilitating condition that causes poor circulation usually in the legs, but may also affect the arms or "peripheral" body organs (that is, any organ other than the brain, the heart, or the lungs).
"The guidelines underscore that there is a growing patient population that suffers from peripheral artery disease and an emergent demand for a wide range of technologies to treat the condition," said Dr. Dennis Donohoe, Vice President, Clinical and Regulatory Affairs, Cordis Corporation. "Such a comprehensive, multidisciplinary look at this common condition is crucial to helping ensure the best possible treatment of the disease. Cordis Endovascular is committed to ensuring that all medical professionals understand and have access to the new treatment guidelines for peripheral artery disease."
The guidelines include an objective review of the benefits of catheter-based therapies, pathways and treatment algorithms to guide clinical decisions, recommended questions and observations for patients and doctors to consider to help uncover signs of PAD and recommendations on when conditions, such as an aneurysm, should be treated with catheter-based therapy or surgery.
The guidelines can be accessed on the AHA and ACC Web sites (http://www.heart.org and http://www.acc.org) and will be published in the Journal of the American College of Cardiology and in Circulation: Journal of the American Heart Association.
With PAD, the arteries supplying blood to the limbs get blocked. Left untreated, PAD increases the risk of heart attack, stroke, amputation, or death.
Cordis Endovascular is committed to serving the cardiology, radiology and vascular surgery communities through the development of groundbreaking technologies for the treatment of peripheral vascular disease. The company constantly seeks solutions to the human anatomy's most challenging problems, such as carotid artery disease, aortic aneurysm, superficial femoral artery disease and venous thrombotic disease. A recognized leader in research and development, Cordis Endovascular has the resources to make breakthrough treatments possible along with the reputation for delivering trusted, quality products and value that is expected by our customers. Cordis Endovascular is a worldwide supplier of interventional and diagnostic medical products including nitinol and stainless steel stents, vena cava filters, balloon catheters and accessories.
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease. For more information about Cordis Corporation, visit http://www.Cordis.com.
Cordis EndovascularCONTACT: Carol Goodrich of Cordis Corporation, Office: +1-908-412-7332,Cell Phone: +1-973-615-4057, cgood2@crdus.jnj.com; Todd Ringler of Edelmanfor Cordis Corporation, Office Phone: +1-781-599-7542, Cell Phone:+1-617-872-1235, todd.ringler@edelman.com